tetano
Editor, Senior Moderator
Cell Rep Med
. 2022 Jul 19;3(7):100685.
doi: 10.1016/j.xcrm.2022.100685.
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
Leonie M Weskamm[SUP] 1 [/SUP], Anahita Fathi[SUP] 2 [/SUP], Matthijs P Raadsen[SUP] 3 [/SUP], Anna Z Mykytyn[SUP] 3 [/SUP], Till Koch[SUP] 2 [/SUP], Michael Spohn[SUP] 4 [/SUP], Monika Friedrich[SUP] 5 [/SUP], MVA-MERS-S Study Group; Bart L Haagmans[SUP] 3 [/SUP], Stephan Becker[SUP] 6 [/SUP], Gerd Sutter[SUP] 7 [/SUP], Christine Dahlke[SUP] 8 [/SUP], Marylyn M Addo[SUP] 2 [/SUP]
Collaborators, Affiliations
Abstract
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.
Keywords: IgG ELISpot; IgG subclasses; MERS-CoV; MVA-MERS-S; immune persistence; late booster vaccination; long-term immunity; memory B cells; neutralizing antibodies; viral vector vaccine.
. 2022 Jul 19;3(7):100685.
doi: 10.1016/j.xcrm.2022.100685.
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
Leonie M Weskamm[SUP] 1 [/SUP], Anahita Fathi[SUP] 2 [/SUP], Matthijs P Raadsen[SUP] 3 [/SUP], Anna Z Mykytyn[SUP] 3 [/SUP], Till Koch[SUP] 2 [/SUP], Michael Spohn[SUP] 4 [/SUP], Monika Friedrich[SUP] 5 [/SUP], MVA-MERS-S Study Group; Bart L Haagmans[SUP] 3 [/SUP], Stephan Becker[SUP] 6 [/SUP], Gerd Sutter[SUP] 7 [/SUP], Christine Dahlke[SUP] 8 [/SUP], Marylyn M Addo[SUP] 2 [/SUP]
Collaborators, Affiliations
- PMID: 35858586
- DOI: 10.1016/j.xcrm.2022.100685
Abstract
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.
Keywords: IgG ELISpot; IgG subclasses; MERS-CoV; MVA-MERS-S; immune persistence; late booster vaccination; long-term immunity; memory B cells; neutralizing antibodies; viral vector vaccine.